KDC-MN-355 – Kodiac biolabs

Plain-language summaryIntrigue 48 / 100

Famotidine, sold as Pepcid, is the most prescribed H2 antihistamine for acid-related gastrointestinal conditions. Unlike H1 blockers used for allergies, H2 blockers reduce gastric acid by blocking histamine signaling at parietal cells in the stomach lining. It is widely used for peptic ulcer disease, GERD, and acid-related upper GI symptoms, with a clean safety profile that allowed OTC availability. The compound briefly attracted attention during the COVID-19 pandemic when retrospective data suggested possible benefit, but prospective trials have been mixed and the proposed anti-inflammatory mechanism remains speculative. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

44/100

Canonical H2 antagonist reference compound with limited novel research upside

Look, famotidine is Pepcid. It’s been sitting in medicine cabinets since 1986 and remains one of the most prescribed OTC compounds on the planet. That’s not a knock on it as a drug. It’s a knock on it as a research frontier.

The mechanism is about as lean as it gets: competitive, highly selective H2 receptor antagonism on gastric parietal cells, suppressing histamine-driven acid output with over 1000-fold selectivity versus H1. Clean pharmacology, well-understood kinetics, renal clearance, short half-life. Theres genuinely nothing under the hood here that a serious investigator hasn’t seen in the literature a hundred times.

The COVID-19 chapter is where things got briefly interesting. Observational data from early 2020 suggested that hospitalized patients taking famotidine had better outcomes, and the proposed mechanisms were legitimately novel for the compound: TMPRSS2 inhibition, sigma-1 receptor modulation, anti-inflammatory effects on immune cell H2 receptors. For a moment it looked like an old drug might have a new story. Then the RCTs came in. The Janowitz et al. pilot was underpowered. The PharmaCyte and larger NIH-supported trials were mostly null or inconclusive. The sigma-1 angle is pharmacologically plausible but the binding affinity data is weak and the clinical signal never materialized in a way that replicated. We think the COVID chapter is closed, or at minimum parked until someone does better mechanistic work on the sigma-1 hypothesis specifically.

Where famotidine does retain genuine research value is as a reference compound for histamine biology. It’s the canonical H2 antagonist you reach for when you want to parse H1 versus H2 contributions in immune cell signaling, gastric mucosa work, or histamine-driven inflammatory models. Ranitidine’s withdrawal due to NDMA contamination actually elevated famotidine’s standing here. Cimetidine has significant CYP450 off-target baggage that famotidine largely avoids. So within the H2 class, famotidine is now the default probe, and that matters for labs doing histamine receptor biology.

But none of that changes the fundamental picture: this is a mature, well-characterized, clinically approved compound with minimal unexplored mechanism space. The evidence base for its primary indications is enormous, which pulls evidence and translational scores up, but that strength is also what makes it boring. Investigators already know what it does. The research conversation has mostly moved on to PPI biology, mucosal repair peptides, and microbiome effects of acid suppression, none of which famotidine is particularly useful for probing. It earns its place as a reference standard. It doesn’t earn much else.

Novelty: 22
Mechanism promise: 23
In-category differentiation: 48
Evidence quality: 70
Translational signal: 63
Research bench value: 50

Rationale Famotidine scores low on novelty and mechanism because it is a 40-year-old, single-receptor blocker in a class largely superseded clinically by PPIs; the COVID-19 investigational angle produced mixed RCTs and the speculative sigma-1/TMPRSS2 mechanisms remain unvalidated. Evidence and translational scores are pulled up by its massive primary-indication trial base, keeping the overall in the low-40s without any cap needing to bind.

H2 receptor antagonist

A second-generation H2 antihistamine; an acid-suppressing agent for peptic ulcers and GERD; investigated for anti-inflammatory and COVID-19 effects.

Abstract

Famotidine (3-({2-[(diaminomethylene)amino]-1,3-thiazol-4-yl}methylsulfanyl)-N-sulfamoyl-propanimidamide; CAS 76824-35-6; molecular formula C8H15N7O2S3; molecular weight 337.45) is a second-generation H2 receptor antagonist developed at Yamanouchi (now Astellas) and approved by the FDA in 1986 (Pepcid). The compound competitively inhibits H2 receptors on gastric parietal cells, reducing histamine-stimulated gastric acid secretion. H2 selectivity over H1 is greater than 1000-fold. Plasma half-life is approximately 2 to 4 hours; renal excretion is the principal clearance pathway. Approved indications: peptic ulcer disease, GERD, Zollinger-Ellison syndrome. The compound attracted attention during the COVID-19 pandemic after observational data suggested possible benefit; randomized controlled trials have produced mixed results, with proposed mechanisms including TMPRSS2 inhibition, sigma-1 modulation, and anti-inflammatory H2 antagonism on immune cells. Used as the canonical H2 antagonist in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-355Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-355

Famotidine

Abstract

Read the full monograph